BiotechTube
Karma Oncology

Karma Oncology

Oxford, United Kingdom· Est.
karmaoncology.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Karma Oncology is a private, revenue-generating services company founded in 2012 (contradicting initial data) that supports biotechs in developing oncology therapies. It offers a full suite of clinical development services, from pre-clinical strategy through trial management, leveraging a lean, virtual team of experienced oncology professionals. The company has expanded internationally with team members in over 20 countries and offices in the UK and US, positioning itself as a specialized partner for emerging biopharma companies navigating complex oncology trials.

Oncology

Technology Platform

Virtual clinical development services platform leveraging a core team of oncology experts and a global network of partners and KOLs to provide end-to-end consulting and trial management.

Opportunities

The booming oncology drug development sector, driven by small biotechs with deep scientific expertise but limited clinical operations infrastructure, presents a large and growing market for specialized service providers.
The increasing complexity of trials, especially in cell/gene therapy (CAR-T, etc.), creates demand for the niche, hands-on expertise Karma offers.

Risk Factors

Revenue is highly dependent on the funding and pipeline stability of small biotech clients, making it vulnerable to downturns in biotech financing.
The company faces intense competition from both large global CROs and smaller niche players in the clinical services market.

Competitive Landscape

Karma competes in the clinical research outsourcing market, facing large, full-service CROs (e.g., IQVIA, PPD) with vast resources and broad reach, as well as other niche oncology-focused CDOs and consultants. Its differentiation lies in its exclusive oncology focus, senior-level virtual team model, and flexibility tailored for emerging biotechs.

More companies in Oncology (General) →More companies in United Kingdom →